<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170871</url>
  </required_header>
  <id_info>
    <org_study_id>0C-08-2</org_study_id>
    <nct_id>NCT01170871</nct_id>
  </id_info>
  <brief_title>Ixabepilone and Pemetrexed/Solid Tumors</brief_title>
  <official_title>Phase I Clinical Trial of Ixabepilone and Pemetrexed in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the maximal tolerated dose (MTD) of Ixabepilone and&#xD;
      Pemetrexed in advanced solid tumors and to obtain preliminary information regarding the&#xD;
      activity of this combination.&#xD;
&#xD;
      This research study is for research participants who have confirmed metastatic or&#xD;
      unresectable solid tumors (lung, breast, ovary, cervix, uterus, mesothelioma, and prostate)&#xD;
      for which standard curative or palliative measures do not exist or no longer effective.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor withdrew support&#xD;
  </why_stopped>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximal tolerated dose (MTD) of Ixabepilone and Pemetrexed in advanced solid tumors.</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>every 42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of Ixabepilone and Pemetrexed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixabepilone</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  SWOG performance status of 0-2.&#xD;
&#xD;
          -  Projected life expectancy of at least 3 months.&#xD;
&#xD;
          -  Female and or male age 18 years and over.&#xD;
&#xD;
          -  Provision of informed consent prior to any study-related procedures.&#xD;
&#xD;
          -  Female patients must not be pregnant due to the potential mutagenicity. and&#xD;
             teratogenicity of this treatment. A pregnancy test must be administered 7 days prior&#xD;
             to administration of therapy to women of childbearing potential.&#xD;
&#xD;
          -  Negative pregnancy test for women of childbearing potential.&#xD;
&#xD;
          -  Patients must agree to use some form of contraception while on this study at&#xD;
             initiation and for the duration of participation in the study. Sexually active males&#xD;
             must also use a reliable and appropriate method of contraception. Post-menopausal&#xD;
             women must be amenorrheic for at least 12 months to be considered of non-childbearing&#xD;
             potential.&#xD;
&#xD;
          -  Patients must have recovered from acute toxicities from previous surgery, chemotherapy&#xD;
             or radiation therapy.&#xD;
&#xD;
          -  Adequate organ function defined as:&#xD;
&#xD;
               -  ANC &gt; 1500/mm3&#xD;
&#xD;
               -  Platelet count &gt; 100,000 cells/mm3&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0g/dL&#xD;
&#xD;
               -  Serum creatinine &lt; 1.5 mg/dl or creatinine clearance &gt; 45 mL/minute&#xD;
&#xD;
               -  (calculated by Cockcroft-Gault formula.)&#xD;
&#xD;
               -  Hepatic function: Patients must have adequate liver functions: AST or ALT &lt; 2.5 X&#xD;
                  upper limit of normal (ULN), alkaline phosphatase &lt; 2.5 X upper limit of normal.&#xD;
                  In patients with bone metastasis and no evidence of liver metastasis and&#xD;
                  bilirubin &lt; upper limit of normal an alkaline phosphatase &lt; 5 ULN will be allowed&#xD;
&#xD;
               -  Serum Bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Peripheral neuropathy grade 0-1.&#xD;
&#xD;
          -  No other concomitant therapy directed at the cancer is allowed.&#xD;
&#xD;
          -  The ability to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs), the day&#xD;
             of, and 2 days following administration of pemetrexed.&#xD;
&#xD;
          -  The ability to take folic acid, Vitamin B12, and dexamethasone according to protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory results:&#xD;
&#xD;
               -  Serum bilirubin &gt; 1.5 the upper limit of reference range (ULRR)&#xD;
&#xD;
               -  Serum creatinine &gt;1.5 x ULRR or creatinine clearance &lt; 45 mL/minute (calculated&#xD;
                  by Cockcroft-Gault formula)&#xD;
&#xD;
          -  Women who are currently pregnant or breast feeding.&#xD;
&#xD;
          -  Receipt of any investigational agents within 30 days prior to commencing study&#xD;
             treatment.&#xD;
&#xD;
          -  Last dose of prior chemotherapy discontinued less than 4 weeks before the start of&#xD;
             study therapy.&#xD;
&#xD;
          -  Last radiation therapy within the last 4 weeks before the start of study therapy,&#xD;
             except palliative radiotherapy.&#xD;
&#xD;
          -  Prior radiation must not have included ≥ 30% of major bone marrow containing areas&#xD;
             (pelvis, lumbar spine).&#xD;
&#xD;
          -  Any unresolved toxicity greater than CTC grade 1 from previous anti- cancer therapy,&#xD;
             excluding alopecia.&#xD;
&#xD;
          -  CTC Grade 1 or greater neuropathy (motor or sensory) at study entry.&#xD;
&#xD;
          -  Hematologic function with absolute neutrophils ≤ 1500/mm3 and/or platelets &lt;&#xD;
             100,000/mm 3.&#xD;
&#xD;
          -  Hepatic function with serum bilirubin greater than the upper institutional limits of&#xD;
             normal, ALT and AST &gt; 2.5 times the upper institutional limits of normal.&#xD;
&#xD;
          -  Presence of third space fluid which cannot be controlled by drainage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agustin Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univrsity of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County+University of Southern California Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 4, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2010</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <name_title>Agustin Garcia, MD</name_title>
    <organization>University of Southern California</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

